Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | LPL | P06858 | 6/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.32 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.32 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16046359 | 0.86 | AAK1 (0.44) | AAK1DGAT1GSK3AGSK3BALPL | |
| SCHEMBL1690283 | 0.84 | AAK1 (0.51) | AAK1DGAT1GSK3AGSK3BALPL | |
| SCHEMBL2409875 | 0.83 | AAK1 (0.47) | AAK1DGAT1GSK3AGSK3BALPL | |
| SCHEMBL6934738 | 0.82 | AAK1 (0.50) | AAK1DGAT1GSK3AGSK3BALPL | |
| SCHEMBL19399966 | 0.81 | AAK1 (0.39) | AAK1DGAT1GSK3AGSK3BFFAR1 | |
| SCHEMBL2068433 | 0.80 | GSK3A (0.38) | AAK1DGAT1GSK3AGSK3BFFAR1 | |
| SCHEMBL30864874 | 0.79 | AAK1 (0.45) | AAK1DGAT1GSK3AGSK3BALPL | |
| SCHEMBL27314904 | 0.79 | AAK1 (0.45) | AAK1DGAT1GSK3AGSK3BALPL | |
| SCHEMBL462679 | 0.79 | AAK1 (0.47) | AAK1DGAT1GSK3AGSK3BALPL | |
| SCHEMBL17609622 | 0.79 | AAK1 (0.39) | AAK1DGAT1GSK3AGSK3BALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3740493-B1 | INHIBTEURS DE L'INDOLEAMINE 2,3-DIOXYGÉNASE ET/OU DU TRYPTOPHANE DIOXYGÉNASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-12-01 | — | — | EP | disclosed |
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-31 | — | — | US | disclosed |
| EP-3740493-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | Idorsia Pharmaceuticals Ltd (CH) | 2020-11-25 | — | — | EP | disclosed |
| US-8013001-B2 | Modulators of LXR | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100056582-A1 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-7482366-B2 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| EP-1773337-A2 | MODULATORS OF NUCLEAR RECEPTORS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006025979-A9 | MODULATORS OF NUCLEAR RECEPTORS | EXELIXIS INC (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006025979-A2 | MODULATORS OF NUCLEAR RECEPTORS | EXELIXIS, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20050080111-A1 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119488-A1 | Modulators Of Nuclear Receptors | NR1H2, NR0B1, NR1H3 | AAK1 2751/4885DGAT1 3233/4885GSK3A 2709/4885 |
| US-20050080111-A1 | Modulators of LXR | NR1H2, NR1H3, NR1H4 | AAK1 2456/4885DGAT1 786/4885GSK3A 1179/4885 |
| US-20100056582-A1 | Modulators of LXR | NR1H2, NR1H3, NR1H4 | AAK1 2456/4885DGAT1 786/4885GSK3A 1179/4885 |
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDO2, TDO2, IDO1 | AAK1 2442/4885DGAT1 1718/4885GSK3A 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.